Evidence map›Paper›PMID 38558766›Full record

ArticleEuropean urology open science2024

Pretreatment Patient-reported Overall Health: A Prognostic Factor for Early Overall Mortality After Primary Curative Treatment of Prostate Cancer.

Sophie D Fosså, Anne Holck Storås, Kirsti Aas, Tom Børge Johannesen, Ylva Maria Gjelsvik, Tor Å Myklebust

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Sophie D FossåDepartment of Oncology, Oslo University Hospital, University of Oslo, Oslo, Norway.
Anne Holck StoråsDepartment of Oncology, Oslo University Hospital, University of Oslo, Oslo, Norway.
Kirsti AasInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Tom Børge JohannesenDepartment of Registration, Cancer Registry of Norway, Oslo, Norway.
Ylva Maria GjelsvikDepartment of Registration, Cancer Registry of Norway, Oslo, Norway.
Tor Å MyklebustDepartment of Registration, Cancer Registry of Norway, Oslo, Norway.
Cancer Registry of Norway · NOAkershus University Hospital · NOOslo University Hospital · NOUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: Registry-based studies for prostate cancer (PCa) document higher overall mortality (OM) after high-dose radiotherapy (RT) than after radical prostatectomy (RP). Our aim was to explore the association between pretreatment patient-reported health ("OverallHealth": OH) and curative treatment type, and the impact on early OM. Methods: New PCa patients registered between 2017 and 2019 in the Cancer Registry of Norway ( Key findings and limitations: Impaired OH was more frequent in the RT group (38%) than in the RP (25%) or AS (28%) group ( Conclusions and clinical implications: Pretreatment patient-reported impaired OH, measured as the QLQ-C30 summary score, was positively associated with allocation to RT or AS and is a prognostic factor for early OM. Before allocation to RT or AS, elderly patients with PCa should be screened and treated for health problems that can be remedied. Future studies should determine the psychometrics of the QLQ-C30 summary score in comparison to established frailty screening instruments. Patient summary: Patient-reported scores reflecting their overall health can help in choosing curative treatment for prostate cancer and are associated with survival during the first 5 years after treatment.

Indexed as

Curative treatmentPretreatment patient-reported healthProstate cancerShort-term overall survivalTreatment choice

Identifiers

PMID38558766
PMCPMC10979064
OpenAlexW4393123833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.